(R)-Lansoprazole-d4

(R)-Lansoprazole-d4

• UNSPSC Description: (R)-Lansoprazole-d4 is deuterium labeled (R)-Lansoprazole. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].
• Target Antigen: Isotope-Labeled Compounds; Proton Pump
• Type: Isotope-Labeled Compounds
• Related Pathways: Membrane Transporter/Ion Channel;Others
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Purity: 99.13
• Solubility: 10 mM in DMSO
• Smiles: O=[S@@](C1=NC2=C([2H])C([2H])=C([2H])C([2H])=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C
• Molecular Weight: 373.39
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.|[3]Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5.|[4]M Miura, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol. 2004 Nov;60(9):623-8.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported